Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Do heavy smokers benefit from higher dose nicotine patch therapy?

J D Killen1, S P Fortmann, L Davis

  • 1Department of Medicine, Stanford University School of Medicine, Palo Alto, California 94304-1825, USA. killen@scrdp.stanford.edu

Experimental and Clinical Psychopharmacology
|September 3, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Does smoking cessation improve health-related quality-of-life?

Annals of behavioral medicine : a publication of the Society of Behavioral Medicine·2013
Same author

Duct-to-duct biliary anastomosis for patients with sclerosing cholangitis undergoing liver transplantation.

Transplantation proceedings·2003
Same author

Nonresponders of interferon/ribavirin treatment for recurrent hepatitis C following liver transplantation.

Transplantation proceedings·2003
Same author

The relationship between agoraphobia symptoms and panic disorder in a non-clinical sample of adolescents.

Psychological medicine·2003
Same author

Effect of Withania somnifera on cell mediated immune responses in mice.

Journal of experimental & clinical cancer research : CR·2003
Same author

Augmentation of coronary conductance in adult sheep made anaemic during fetal life.

The Journal of physiology·2003

This study found that a higher dose (25 mg) nicotine patch did not significantly improve smoking cessation rates compared to a standard dose (15 mg) for heavy smokers. Both doses were well-tolerated, with similar adverse events reported.

Area of Science:

  • Addiction Medicine
  • Pharmacology
  • Clinical Trials

Background:

  • Nicotine dependence is a significant public health issue.
  • Nicotine replacement therapy (NRT) is a common smoking cessation aid.
  • Optimizing NRT dosage for heavy smokers requires further investigation.

Purpose of the Study:

  • To compare the efficacy of high-dose (25 mg) versus standard-dose (15 mg) nicotine patch therapy for smoking cessation in heavy smokers.
  • To assess the safety and tolerability of different nicotine patch doses.
  • To identify predictors of relapse in smoking cessation.

Main Methods:

  • Randomized controlled trial involving 408 heavy smokers (≥25 cigarettes/day).
  • Participants received either 15 mg or 25 mg nicotine patch therapy for 16 hours/day over 6 weeks.

Related Experiment Videos

  • Follow-up assessments at 2, 6, and 12 months to determine smoking status.
  • Cox proportional hazards analyses were used to identify relapse predictors.

    • Main Results:

    • Smoking cessation rates were similar between the 15-mg and 25-mg nicotine patch groups at all follow-up points (2, 6, and 12 months).
    • The higher dose nicotine patch was well-tolerated, with comparable adverse event profiles to the standard dose.
    • Initial postrandomization craving and baseline depression scores predicted time-to-relapse during treatment, while only initial craving predicted relapse over 12 months.

    Conclusions:

    • Higher-dose (25 mg) nicotine patch therapy does not offer superior smoking cessation efficacy compared to standard-dose (15 mg) therapy for heavy smokers.
    • Routine use of higher-dose nicotine patch therapy is not supported by these findings.
    • Craving is a significant predictor of relapse in smoking cessation interventions.